Blog

  • Alcaraz, Sinner chase first Paris trophy: Scouting Report – ATP Tour

    1. Alcaraz, Sinner chase first Paris trophy: Scouting Report  ATP Tour
    2. Carlos Alcaraz Mirrors Roger Federer’s Sentiments as He Poises to End Jannik Sinner’s Reign At Paris Masters  EssentiallySports
    3. Carlos Alcaraz’s Paris Masters Draw is…

    Continue Reading

  • Trump Administration Live Updates: President to Start Asia Visit With Tariffs and China on Agenda – The New York Times

    1. Trump Administration Live Updates: President to Start Asia Visit With Tariffs and China on Agenda  The New York Times
    2. Ukraine war: Trump hopes China will help bring end to Russia war  BBC
    3. Trump travels to Asia and a meeting with China’s Xi as the…

    Continue Reading

  • Life in the age of AI and abundance

    Life in the age of AI and abundance

    By: R.K. Pillai

    Imagine the dawn of the 22nd century. Technological advancements have created surplus societies across the globe. AGI and ASI have transformed production, distribution, and consumption to near-optimal efficiency. Human…

    Continue Reading

  • 4 ways to lower cancer risk in young adults, according to experts |

    4 ways to lower cancer risk in young adults, according to experts |

    Image credits: Getty Images

    Life is meant to end but not in your 20s, 30s and 40s. Sadly, this is what has the experts in fear for the lives of youngsters across the world. According to the National Cancer Institute’s estimates for 2025, 4.2% of…

    Continue Reading

  • 5 ways low levels can impact body and health

    5 ways low levels can impact body and health

    Vitamin D, often called the “sunshine vitamin,” is essential for maintaining overall health. It is unique among vitamins because the body can produce it when the skin is exposed to sunlight. Additionally, it can be obtained through certain…

    Continue Reading

  • Want to live longer? How new drugs, AI and daily habits can extend lifespan

    Want to live longer? How new drugs, AI and daily habits can extend lifespan

    Million-dollar longevity clinics, IV drips, personalised genome sequencing – the quest for a longer, healthier life often feels like a science fiction movie with an exclusive ticket price.

    But as the wellness industry chases expensive, hi-tech…

    Continue Reading

  • F1 Qualifying RECAP: Lando Norris takes pole at Mexico City Grand Prix 2025

    F1 Qualifying RECAP: Lando Norris takes pole at Mexico City Grand Prix 2025

    1

    Lando Norris

    McLaren

    4

    fastest lap 1:16.252
    fastest lap 1:16.252
    fastest lap 1:15.586
    fastest lap 1:15.586

    Qualifying 3, fastest lap 1:15.586

    2

    Charles Leclerc

    Monaco

    Ferrari

    16

    Qualifying 3,…

    Continue Reading

  • Implications for the global HIV response

    Implications for the global HIV response

    In 2024, an estimated 40 million people were living with HIV. While 77 % were being treated, nine million were not. Despite progress, the HIV response faces growing challenges due to shifting funding and political uncertainty. The US, which…

    Continue Reading

  • Can Schrödinger (SDGR) Sustain Its AI Edge in Drug Discovery as Q3 Results Approach?

    Can Schrödinger (SDGR) Sustain Its AI Edge in Drug Discovery as Q3 Results Approach?

    • Schrödinger announced it will release its third quarter 2025 financial results on November 5, 2025, followed by a live webcast and conference call for investors.

    • The company has attracted increasing industry attention as a pioneer in applying artificial intelligence to accelerate drug discovery and reshape biotechnology innovation.

    • We’ll explore how recognition of Schrödinger’s AI leadership amid growing sector focus may influence its long-term investment outlook.

    Find companies with promising cash flow potential yet trading below their fair value.

    To be a shareholder of Schrödinger, you need to believe the company’s AI-driven software can become essential to drug discovery, leading to scalable, recurring revenues and clinical milestones. The upcoming third quarter 2025 results announcement and investor call, while relevant for short-term sentiment, does not materially change the main near-term catalyst, new clinical data for SGR-1505, nor does it resolve the biggest risk of sluggish new client acquisition amid biotech sector headwinds.

    The most closely related recent announcement is Schrödinger’s update on initial clinical results for SGR-1505, a MALT1 inhibitor, which showed early efficacy and received FDA Fast Track designation this June. This progress in the clinic positions SGR-1505 as a primary driver for milestone payments and licensing, supporting management’s focus on revenue growth from drug discovery and anchoring the short-term investment outlook.

    However, investors should also be mindful that, in contrast to the excitement around new clinical milestones, ongoing challenges in expanding the customer base persist and…

    Read the full narrative on Schrödinger (it’s free!)

    Schrödinger’s narrative projects $396.6 million revenue and $34.8 million earnings by 2028. This requires 18.6% yearly revenue growth and a $216.1 million increase in earnings from the current level of -$181.3 million.

    Uncover how Schrödinger’s forecasts yield a $27.30 fair value, a 21% upside to its current price.

    SDGR Community Fair Values as at Oct 2025

    Six independent valuations from the Simply Wall St Community place fair value for Schrödinger between US$27.00 and US$43.20 per share. While some see upside, many remain focused on the risk that slow new client acquisition could constrain long-term revenue growth and influence market sentiment ahead of earnings; explore the range of outlooks shaping this debate.

    Explore 6 other fair value estimates on Schrödinger – why the stock might be worth as much as 92% more than the current price!

    Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

    Don’t miss your shot at the next 10-bagger. Our latest stock picks just dropped:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include SDGR.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • A Fresh Look at Valuation After Sector Jitters Triggered by Texas Instruments Forecast

    A Fresh Look at Valuation After Sector Jitters Triggered by Texas Instruments Forecast

    Shares of Skyworks Solutions (SWKS) slipped 3% after a disappointing outlook from Texas Instruments. This development heightened concerns about a slowing recovery across the broader semiconductor industry and cast a shadow over sector performance.

    See our latest analysis for Skyworks Solutions.

    Against the backdrop of sector-wide jitters sparked by Texas Instruments’ outlook, Skyworks Solutions’ share price has lost ground this month and year-to-date, with a 1-year total shareholder return of -19%. While the company continues to roll out technical advances and earn industry recognition, recent momentum is clearly fading as investors reassess risk across the entire semiconductor space.

    Curious to see which other chipmakers might be showing resilience or fresh growth? You can spot new opportunities with our tech and AI stocks screener using See the full list for free.

    With shares now trading well below their five-year highs and sentiment at a low, the crucial question for investors is whether Skyworks Solutions is an undervalued opportunity or if the market is accurately pricing in future challenges and limited growth ahead.

    Skyworks Solutions’ last close of $74.04 stands slightly above the most-followed narrative’s fair value calculation of $72.47. Analyst consensus believes that near-term improvements may be limited, which sets the stage for ongoing debate around whether today’s market price is justified or too optimistic.

    Accelerated adoption of advanced wireless standards and AI-capable smartphones is increasing the RF content required per device. This positions Skyworks to benefit from higher average selling prices and potential unit volume growth, and may drive revenue and gross margin expansion.

    Read the complete narrative.

    What forecast is powering this valuation? The narrative quietly hinges on a projected turnaround in profit margins, a wave of new revenue sources, and bold expectations for industry cycles. The real surprise is how consensus thinks Skyworks will overcome recent headwinds. Wonder what hidden lever is at the core? Explore the full story to see which future assumptions could send shares in either direction.

    Result: Fair Value of $72.47 (OVERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, risks remain, such as Skyworks’ reliance on a single major customer and persistent competition. Either factor could challenge even the most optimistic scenario.

    Find out about the key risks to this Skyworks Solutions narrative.

    While the analyst consensus suggests Skyworks Solutions is fairly valued or slightly overvalued using market multiples, our DCF model tells a different story. The SWS DCF model estimates fair value at $110.36 per share, which is far above today’s price. This hints at a meaningful undervaluation the market could be overlooking. Can this gap persist, or will investors eventually close it?

    Look into how the SWS DCF model arrives at its fair value.

    SWKS Discounted Cash Flow as at Oct 2025

    If you see things differently, or want to bring your own perspective to the numbers, crafting your own narrative takes just a few minutes. Do it your way

    A great starting point for your Skyworks Solutions research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.

    Take action now and supercharge your watchlist by targeting untapped markets, growth leaders, or stable income opportunities before the crowd catches on.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include SWKS.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading